More-sensitive enzyme-multiplied immunoassay technique for procainamide and N-acetylprocainamide in plasma, serum, and urine.
A commercially available (Syva Co.) enzyme-multiplied immunoassay technique (EMIT) for the quantitative determination of procainamide (PA) and N-acetylprocainamide (NAPA) was modified to allow automated quantitative analysis of approximately 100 samples per day, in a working range of 0.1 to 2.0 micrograms/mL. Such a test was needed to evaluate the pharmacokinetic characteristics of controlled-release dosage forms characterized by long half-lives at low plasma concentration. Analytical recovery of PA and NAPA from serum, plasma, and urine was satisfactory, but at extreme ratios for PA:NAPA the accuracy of determining the lower-concentration component became unsatisfactory. In fact, however, we found no such ratios in 5400 clinical samples assayed by this procedure.
D000120:Acecainide / Q000032:analysis* / Q000097:blood / Q000652:urine; D001322:Autoanalysis / Q000379:methods; D006801:Humans; D007124:Immunoenzyme Techniques; D011342:Procainamide / Q000031:analogs & derivatives* / Q000032:analysis* / Q000097:blood / Q000652:urine
D000120:Acecainide; D011342:Procainamide